PALYNZIQ Now Approved for Children 12+ with PKU | Medscape

The U.S. Food and Drug Administration (FDA) has expanded the approval of PALYNZIQ® (pegvaliase-pqpz), a treatment for phenylketonuria (PKU), to include adolescents as young as 12 years old. Previously, the medication was only approved for adult patients with this rare, inherited metabolic disorder. This expansion offers a new therapeutic option for teenagers navigating the challenges of managing PKU during a critical period of development.

Understanding Phenylketonuria (PKU)

Phenylketonuria, or PKU, is a genetic condition where the body lacks the enzyme needed to break down phenylalanine (Phe), an amino acid found in protein. If left untreated, Phe builds up in the blood, leading to serious neurological problems, including intellectual disability, seizures, and behavioral issues. Medscape reports that the condition affects roughly 1 in 10,000 to 1 in 15,000 newborns in the United States. Newborns are routinely screened for PKU as part of standard newborn screening programs.

Management of PKU traditionally relies on a strict, lifelong diet severely restricting phenylalanine intake. This can be incredibly challenging, particularly during adolescence when dietary adherence often declines due to increasing independence and social pressures. Poor control of blood Phe levels can have significant neurocognitive consequences, making the availability of alternative treatments like PALYNZIQ particularly critical.

PALYNZIQ: An Enzyme Substitution Therapy

PALYNZIQ represents a novel approach to PKU treatment. It’s the only enzyme substitution therapy currently approved for the condition. Instead of restricting Phe intake, PALYNZIQ provides the missing enzyme, pegvaliase-pqpz, which breaks down Phe in the body. BioMarin, the pharmaceutical company that manufactures PALYNZIQ, announced the FDA approval on February 27, 2026, following data from the PEGASUS study.

The PEGASUS Study and its Findings

The PEGASUS study was a Phase 3, multi-center, open-label, randomized controlled trial evaluating PALYNZIQ’s safety and efficacy in adolescents (aged 12 to under 18) with PKU who had uncontrolled blood Phe concentrations exceeding 600 µmol/L despite existing management strategies. The study demonstrated that PALYNZIQ led to statistically significant reductions in blood Phe levels compared to diet alone. This suggests that the medication can aid bring Phe levels into a more normal range, even whereas allowing for a less restrictive diet.

Dr. Stephanie Sacharow, Director of the Dr. Harvey Levy Program for PKU and Related Conditions at Boston Children’s Hospital, highlighted the importance of this approval, noting that adolescence is a particularly challenging time for PKU management. She observed that treatment adherence with PALYNZIQ is often more successful in teens still living at home with family support.

What This Means for Adolescents with PKU

The expanded approval of PALYNZIQ offers a potentially life-changing option for adolescents with PKU who struggle to maintain adequate control of their Phe levels through diet alone. The ability to reduce dietary restrictions while maintaining acceptable Phe levels could significantly improve quality of life, allowing for greater social participation and academic success. However, it’s crucial to understand that PALYNZIQ is not a cure for PKU. It requires ongoing monitoring and management by a qualified clinician.

It’s also important to note that PALYNZIQ is genotype-independent, meaning its effectiveness isn’t tied to the specific genetic mutation causing PKU in an individual. This broad applicability makes it a valuable treatment option for a wider range of patients.

Potential Adverse Effects and Considerations

As with any medication, PALYNZIQ is associated with potential adverse effects. Medscape details frequency-based adverse effects, comprehensive interactions, and contraindications. Common side effects reported in clinical trials include injection site reactions, nausea, and vomiting. Serious hypersensitivity reactions, including anaphylaxis, have also been reported, necessitating administration of the medication in a setting where immediate medical support is available. Patients and caregivers should discuss the potential risks and benefits of PALYNZIQ with their healthcare provider.

The Future of PKU Treatment and Research

The approval of PALYNZIQ for adolescents represents a significant step forward in the treatment of PKU. However, research continues to explore new and improved therapies, including gene therapy and other enzyme substitution approaches. Ongoing surveillance of PALYNZIQ’s long-term safety and efficacy will be crucial, as will further studies to identify which patients are most likely to benefit from this treatment. The FDA approval process will continue to be informed by data from clinical trials and real-world evidence gathered after the drug’s release.

For families and individuals affected by PKU, staying informed about the latest developments in treatment and management is essential. Reliable sources of information include the National PKU Alliance (https://npkua.org/) and the PKU News website (https://pkunews.org/). Regular consultation with a qualified clinician specializing in metabolic disorders is also vital for personalized care and optimal outcomes.